Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors, on Tuesday announced the successful completion of patient enrollment in its Phase 1b/2a CENDIFOX trial.
This investigator-initiated trial is evaluating the safety and efficacy of Lisata's iRGD cyclic peptide product candidate, Certepetide, in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.